Ipsen S.A. (IPSEF)
- Globe Newswire
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases CHMP positive opinion for Iqirvo® (elafibranor) recommended for the treatment of primary biliary cholangitis, following FDA approval in June 2024 CHMP positive opinion for Kayfanda® (odevixibat) recommended for cholestatic pruritus in patients with Alagille syndromeFinal European Commission decision for both medicines
- GlobeNewswire
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
PARIS, FRANCE, 25 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2024. Business highlights U.S. regulatory approvals and launches of Onivyde® (irinotecan) in first-line pancreatic cancer and Iqirvo® (elafibranor) in second-line primary biliary cholangitis, respectivelyIn-licensing of tovorafenib outside the U.S.: an attractive addition to our Oncology pipelineMultiple early-stage extern
- GlobeNewswire
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
Ipsen secures ex-U.S. regulatory and commercial rights to tovorafenib for most common childhood brain tumor, pediatric low-grade glioma (pLGG), and any future indicationsOJEMDA™ (tovorafenib) is the first FDA-approved treatment for relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or V600 mutation, following the pivotal Phase II trial, FIREFLY-1Day One receives approximately $111 million upfront in cash and equity investment with up to approximately $350 million in milestone
